Oligoprogressive

12 registered clinical trials studyying Oligoprogressive — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) NCT04974671	Yale University	Phase 2
Recruiting	Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer NCT06585007	Universitaire Ziekenhuizen KU Leuven	Phase 3
Recruiting	LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE) NCT06103682	University of California, Davis	N/A
Recruiting	Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER) NCT06101290	University of California, Davis	N/A
Recruiting	Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) NCT06101277	University of California, Davis	N/A
Recruiting	Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS) NCT06103669	University of California, Davis	N/A
Terminated	Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies NCT05846659	ImmuneSensor Therapeutics Inc.	Phase 2
Recruiting	COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Can NCT05301881	The Netherlands Cancer Institute	Phase 2
Recruiting	Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic NCT04989725	Centre hospitalier de l'Université de Montréal (CHUM)	Phase 2
Unknown	A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression NCT04970693	Sun Yat-sen University	Phase 2
Withdrawn	Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma NCT04485026	Wake Forest University Health Sciences	Phase 2
Recruiting	Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer NCT04838899	Sunnybrook Health Sciences Centre	N/A